Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 17 · below the Ichimoku cloud · RSI 51 · MACD above its signal
| 1.51 | 52-week high | +297.79% |
| 0.6591 | R3 (classic) | +73.64% |
| 0.5463 | R2 (classic) | +43.91% |
| 0.4726 | R1 (classic) | +24.51% |
| 0.4442 | Previous month high | +17.02% |
| 0.4334 | Previous day high | +14.17% |
| 0.4210 | Previous week high | +10.91% |
| 0.3796 | Price now | |
| 0.3598 | Pivot | −5.22% |
| 0.3100 | Previous week low | −18.34% |
| 0.3021 | Previous month low | −20.42% |
| 0.2861 | S1 (classic) | −24.62% |
| 0.2469 | Previous day low | −34.96% |
| 0.2469 | 52-week low | −34.96% |
| 0.1733 | S2 (classic) | −54.36% |
| 0.0996 | S3 (classic) | −73.75% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $29.3K | 0.00% | 37.99K | −33% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PMCB trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jan 6, 2026 | Schechter Jonathan LDirector | Purchase at price 0.78 - 0.84 per share. | 60K | $48.23K |
| Dec 11, 2025 | Weinstein RobertDirector | Stock Award(Grant) at price 0.00 per share. | 75K | — |
| Dec 11, 2025 | Walker Wayne RemellDirector | Stock Award(Grant) at price 0.00 per share. | 37.5K | — |
| Dec 11, 2025 | Schechter Jonathan LDirector | Stock Award(Grant) at price 0.00 per share. | 150K | — |
| Dec 11, 2025 | Abecassis Michael M. M.D.Director | Stock Award(Grant) at price 0.00 per share. | 37.5K | — |
TimeframesDown on the weekly and monthly, mixed on the hourly and daily.
pulling back under the 21 EMA
bouncing over the 21 EMA
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 13.1 | -15.7 | -3.6 | 8.5 | 15.6 | -7.7 | -25.2 | -13.0 | -18.0 | -26.4 | 25.7 | −47.6% | |
| 2025 | 2.2 | 9.9 | -29.1 | -0.8 | -17.3 | 6.3 | -6.4 | -7.9 | 3.3 | -4.1 | -16.8 | -6.4 | −53.9% |
| 2024 | 1.4 | -4.1 | 12.9 | -10.5 | -7.5 | 0.0 | 0.0 | -21.9 | 24.8 | -5.2 | -5.5 | -8.2 | −27.3% |
| 2023 | -1.4 | 3.8 | -3.0 | 0.3 | 7.9 | -9.2 | -7.0 | -7.9 | -14.3 | 1.0 | 6.6 | -4.4 | −26.3% |
| 2022 | -14.4 | -0.5 | 8.0 | 1.3 | -1.3 | -2.6 | 6.7 | 10.0 | -8.7 | 22.5 | 2.7 | -3.0 | +17.2% |
| 2021 | 168.7 | 55.6 | -38.9 | 3.5 | -28.2 | -15.0 | -28.3 | -71.9 | -5.9 | -11.0 | -8.2 | -3.5 | −75.9% |
| 2020 | 38.3 | -8.9 | -41.2 | -18.3 | -21.2 | 33.2 | -45.5 | -15.0 | 42.9 | -47.6 | -32.6 | 11.7 | −83.5% |
| 2019 | 13.0 | 27.8 | -9.0 | -15.6 | -7.1 | 2.4 | 1.3 | -12.4 | 6.4 | -4.9 | -1.4 | 17.4 | +9.5% |
| 2018 | 28.9 | -21.4 | -6.5 | 2.3 | -3.9 | 31.6 | -18.0 | -6.3 | 9.0 | -9.1 | -7.3 | -23.2 | −33.7% |
| 2017 | -23.1 | -2.9 | -11.4 | -20.9 | -16.6 | -13.7 | 37.3 | -22.1 | -3.3 | -7.8 | -10.3 | 16.2 | −62.5% |
| 2016 | 41.1 | -9.4 | 10.0 | 5.9 | 2.2 | -21.9 | -4.6 | -29.5 | -4.9 | 5.7 | 75.7 | 129.1 | +223.7% |
| 2015 | -40.2 | 7.7 | 20.2 | 11.3 | -7.2 | -14.7 | -5.8 | -15.4 | -9.2 | 21.8 | -20.7 | -46.5 | −74.4% |
| 2014 | 80.8 | 133.2 | -22.1 | -12.0 | -5.7 | -7.1 | 8.0 | -17.6 | -19.2 | 23.0 | -7.7 | -14.7 | +76.5% |
| 2013 | 77.1 | 49.2 | 32.0 | 46.6 | -24.5 | 40.7 | -11.6 | -5.4 | 2.0 | 6.0 | -23.3 | +276.4% |
No analyst coverage for this instrument.
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.